Obesity not a 'zero-sum game' as patients crave optionality, Novo CEO says: Reuters

As the massive market for GLP-1 weight-loss drugs continues to come into its own, patients are just now discovering their preferences, and the appetite for differentiation will likely increase as more drugs are approved in the indication, Novo Nordisk's CEO told Reuters.